Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

SAB Biotherapeutics (SABS) Operating Expenses: 2020-2024

Historic Operating Expenses for SAB Biotherapeutics (SABS) over the last 5 years, with Dec 2024 value amounting to $44.2 million.

  • SAB Biotherapeutics' Operating Expenses rose 12.11% to $12.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $43.3 million, marking a year-over-year decrease of 18.73%. This contributed to the annual value of $44.2 million for FY2024, which is 9.72% up from last year.
  • According to the latest figures from FY2024, SAB Biotherapeutics' Operating Expenses is $44.2 million, which was up 9.72% from $40.3 million recorded in FY2023.
  • Over the past 5 years, SAB Biotherapeutics' Operating Expenses peaked at $74.3 million during FY2021, and registered a low of $34.7 million during FY2020.
  • Moreover, its 3-year median value for Operating Expenses was $44.2 million (2024), whereas its average is $45.8 million.
  • As far as peak fluctuations go, SAB Biotherapeutics' Operating Expenses surged by 114.15% in 2021, and later dropped by 28.88% in 2022.
  • SAB Biotherapeutics' Operating Expenses (Yearly) stood at $34.7 million in 2020, then spiked by 114.15% to $74.3 million in 2021, then dropped by 28.88% to $52.8 million in 2022, then decreased by 23.68% to $40.3 million in 2023, then grew by 9.72% to $44.2 million in 2024.